Vimarsana
Biggest News Aggregation in the World

Page 10 - Systemic Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Systemic Sclerosis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Systemic Sclerosis Today - Breaking & Trending Today

BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO) - Vimarsana News

BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)

INSIDE INFORMATION Combination of ATO with copper salts will allow BioSenic to work towards reducing the dosage of ATO in future trials overall and maintain efficacy Mont-Saint-Guibert,... | March 30, 2023

CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022 - Vimarsana News

CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022

/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced full year 2022 financial results and...

Call It Preclinical or Subclinical, ILD in RA Needs to Be Tracked - Vimarsana News

Call It Preclinical or Subclinical, ILD in RA Needs to Be Tracked

Despite ILD being a leading cause of death in RA patients, there are no clinical guidelines for monitoring this lung condition in this population, experts say.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS - Vimarsana News

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS

/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022...

BioSenic announces initiation of coverage by Portzamparc and Gilbert Dupont - Vimarsana News

BioSenic announces initiation of coverage by Portzamparc and Gilbert Dupont

Mont-Saint-Guibert, Belgium, February 14, 2023, 5:45 pm CET – BioSenic , the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today... | February 14, 2023